非布索坦最小服用剂量

(febuxostat), as a new type of non-purine xanthine oxidase inhibitor with a different structure from allopurinol, has a significant inhibitory effect on both oxidized and reduced XOR. Therefore, its uric acid-lowering effect is more powerful and lasting, and it can safely and effectively reduce uric acid levels in patients. So, what is the minimum dose of febuxostat when patients use this drug?

According to the recommended usage of febuxostat, the recommended starting dose is 40 mg/d, with the SUA reduced to less than 360 μmol/L as the target standard. After reaching the target during treatment, the dose is changed to 20 mg/d orally for continuous administration. For patients who have not reached the target after taking 40 mg/d for 1 week, the dose is increased to 80 mg/d. In other words, the minimum dose of febuxostat is 40 mg/d.

Multiple research results show that the most common adverse reactions of Febuxostat (Febuxostat) are abnormal liver function, rash, diarrhea, headache, nausea, vomiting, abdominal pain, dizziness, joint pain and musculoskeletal symptoms, and most of the adverse reactions are mild to moderate. Febuxostat has a higher incidence of adverse cardiovascular events (including myocardial infarction, stroke, and cardiovascular death) than allopurinol, but there is no statistical significance. Cardiovascular adverse events have nothing to do with the dose or duration of administration of febuxostat. They are considered to be related to gout, because hyperuricemia has been considered an independent risk factor for cardiovascular events and is also part of the metabolic syndrome.

In order to minimize adverse reactions caused by improper medication, during the actual treatment with febuxostat, patients must not only master the correct medication method, but also closely monitor changes in their own physical signs. Once any uncomfortable reactions occur, effective measures must be taken to deal with them.

Recommended hot articles: /newsDetail/79125.html